Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

BCMA-CD19 bispecific CAR-T - Hunan Siweikang Therapeutics

Next Previous
X
Search
Drug Profile

BCMA-CD19 bispecific CAR-T - Hunan Siweikang Therapeutics

Alternative Names: SAFET BCMA/CD19 BiCART; SWK-001

Latest Information Update: 24 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hunan Siweikang Therapeutics
  • Class Antineoplastics; CAR-T cell therapies; Cell therapies; T lymphocyte cell therapies
  • Mechanism of Action Interleukin 1 inhibitors; Interleukin 18 replacements; Interleukin 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I B-cell lymphoma; Lymphoid leukaemia; Multiple myeloma; Ovarian cancer

Most Recent Events

  • 31 May 2024 Efficacy and adverse event data from a phase I trial in B-cell lymphoma, multiple myeloma, ovarian cancer and lymphoid leukemia presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 12 Apr 2020 Phase-I clinical trials in B-cell lymphoma (Second-line therapy or greater) in China (Parenteral) (ChiCTR2000032124)
  • 12 Apr 2020 Phase-I clinical trials in Lymphoid leukaemia (Second-line therapy or greater) in China (Parenteral) (ChiCTR2000032124)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top